Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712669 | 0.89 | — | — | |
| SCHEMBL8056802 | 0.89 | — | — | |
| SCHEMBL140296 | 0.89 | — | — | |
| SCHEMBL20610565 | 0.82 | TSHR (0.33) | TSHRTDP1SHBG | |
| SCHEMBL9496745 | 0.82 | TSHR (0.33) | TSHRTDP1SHBG | |
| SCHEMBL5271101 | 0.81 | TRPA1 (0.30) | TRPA1TRPM8 | |
| SCHEMBL26111758 | 0.80 | SHBG (0.50) | TSHRTDP1JAK3SHBG | |
| SCHEMBL8671923 | 0.79 | — | — | |
| SCHEMBL20627575 | 0.79 | — | — | |
| SCHEMBL6092895 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240410055-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20140148623-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148623-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148623-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8450549-B2 | Fuel compositions comprising isoprene derivatives | DANISCO US INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450549-B2 | Fuel compositions comprising isoprene derivatives | DANISCO US INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450549-B2 | Fuel compositions comprising isoprene derivatives | DANISCO US INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2448891-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | Danisco US Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2010148256-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010148256-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | PKN2, OPRD1, PKN1 | TRPA1 215/4885TRPM8 487/4885TSHR 3161/4885 |
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | GGPS1, FNTA, COASY | TRPA1 3513/4885TRPM8 4386/4885TSHR 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.